ALK and neuroblastoma: We validated our protocols in a panel of 15 neuroblastoma cell lines and 2 MYC-amplified non-neuroblastoma cell lines to control for assay specificity, and reveal evidence for different MYCN or ALK status than previously reported for 7 cell lines commonly used in research.